CLOVIQUE (trientine hydrochloride) · CHARTWELL RX
CLOVIQUE is FDA-approved to treat 4 conditions (same as SYPRINE).
Details
- Status
- Discontinued
- First Approved
- 2019-10-21
- Routes
- ORAL
- Dosage Forms
- CAPSULE
CLOVIQUE Approval History
What CLOVIQUE Treats
4 indicationsCLOVIQUE is approved for 4 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Wilson’s Disease
- Cystinuria
- Rheumatoid Arthritis
- Biliary Cirrhosis
Same approved indications as SYPRINE (same active ingredient).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CLOVIQUE FDA Label Details
Indications & Usage
CLOVIQUE is FDA-approved to treat 4 conditions — same approved indications as SYPRINE.
Track CLOVIQUE with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.